ijms-logo

Journal Browser

Journal Browser

Mechanisms of Metastasis in Pancreatic Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 2456

Special Issue Editor


E-Mail Website
Guest Editor
Cedars-Sinai Medical Center, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA
Interests: pancreatic cancer; metastasis; chemo-resistance; drug development; risk factors of cancer

Special Issue Information

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive disease with limited options in terms of effective therapies. The five-year survival rate for PDAC patients is estimated at 7%, making it the sixth most common cancer-related cause of death even though it is the twelfth in incidence. A major reason for this devastating outcome is the high metastatic rate of the disease combined with a lack of effective strategies for early detection and treatment of metastasis. Nearly 80% of the diagnosed patients have regional or distal metastasis. At autopsy, it was found that over 80% of PDAC patients have liver metastasis and nearly 45% have lung metastasis.

Preventing and/or treating PDAC metastasis will significantly improve the outcome of pancreatic cancer drugs. Therefore, understanding the mechanism of metastasis is crucial to overcome this burden. This Special Issue aims to develop novel insights to overcome PDAC metastasis. This includes novel concepts for the detection, prevention, and treatment of metastasis.

Dr. Mouad Edderkaoui
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • metastasis
  • chemo-resistance
  • drug development
  • risk factors of cancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 5562 KiB  
Article
Pan-Sigma Receptor Modulator RC-106 Induces Terminal Unfolded Protein Response In In Vitro Pancreatic Cancer Model
by Michela Cortesi, Alice Zamagni, Sara Pignatta, Michele Zanoni, Chiara Arienti, Daniela Rossi, Simona Collina and Anna Tesei
Int. J. Mol. Sci. 2020, 21(23), 9012; https://doi.org/10.3390/ijms21239012 - 27 Nov 2020
Cited by 6 | Viewed by 2054
Abstract
Pancreatic cancer (PC) remains one of the most lethal cancers worldwide. Sigma receptors (SRs) have been proposed as cancer therapeutic targets. Their main localization suggests they play a potential role in ER stress and in the triggering of the unfolded protein response (UPR). [...] Read more.
Pancreatic cancer (PC) remains one of the most lethal cancers worldwide. Sigma receptors (SRs) have been proposed as cancer therapeutic targets. Their main localization suggests they play a potential role in ER stress and in the triggering of the unfolded protein response (UPR). Here, we investigated the mechanisms of action of RC-106, a novel pan-SR modulator, to characterize therapeutically exploitable role of SRs in tumors. Two PC cell lines were used in all the experiments. Terminal UPR activation was evaluated by quantifying BiP, ATF4 and CHOP by Real-Time qRT-PCR, Western Blot, immunofluorescence and confocal microscopy. Cell death was studied by flow cytometry. Post-transcriptional gene silencing was performed to study the interactions between SRs and UPR key proteins. RC-106 activated ER stress sensors in a dose- and time-dependent manner. It also induced ROS production accordingly with ATF4 upregulation at the same time reducing cell viability of both cell lines tested. Moreover, RC-106 exerted its effect through the induction of the terminal UPR, as shown by the activation of some of the main transducers of this pathway. Post-transcriptional silencing studies confirmed the connection between SRs and these key proteins. Overall, our data highlighted a key role of SRs in the activation of the terminal UPR pathway, thus indicating pan-SR ligands as candidates for targeting the UPR in pancreatic cancer. Full article
(This article belongs to the Special Issue Mechanisms of Metastasis in Pancreatic Cancer)
Show Figures

Figure 1

Back to TopTop